JPWO2020081741A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020081741A5 JPWO2020081741A5 JP2021520923A JP2021520923A JPWO2020081741A5 JP WO2020081741 A5 JPWO2020081741 A5 JP WO2020081741A5 JP 2021520923 A JP2021520923 A JP 2021520923A JP 2021520923 A JP2021520923 A JP 2021520923A JP WO2020081741 A5 JPWO2020081741 A5 JP WO2020081741A5
- Authority
- JP
- Japan
- Prior art keywords
- reduce
- pharmaceutical composition
- fold
- agent
- decrease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024031893A JP2024063161A (ja) | 2018-10-16 | 2024-03-04 | 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法 |
| JP2025076487A JP2025118759A (ja) | 2018-10-16 | 2025-05-02 | 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862746524P | 2018-10-16 | 2018-10-16 | |
| US62/746,524 | 2018-10-16 | ||
| US201862747587P | 2018-10-18 | 2018-10-18 | |
| US62/747,587 | 2018-10-18 | ||
| US201962838049P | 2019-04-24 | 2019-04-24 | |
| US62/838,049 | 2019-04-24 | ||
| PCT/US2019/056616 WO2020081741A2 (en) | 2018-10-16 | 2019-10-16 | Compositions and methods for treating vascular ehlers danlos syndrome and associated disorders |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024031893A Division JP2024063161A (ja) | 2018-10-16 | 2024-03-04 | 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法 |
| JP2025076487A Division JP2025118759A (ja) | 2018-10-16 | 2025-05-02 | 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022504990A JP2022504990A (ja) | 2022-01-13 |
| JPWO2020081741A5 true JPWO2020081741A5 (https=) | 2022-09-20 |
| JP2022504990A5 JP2022504990A5 (https=) | 2022-09-20 |
| JP7678748B2 JP7678748B2 (ja) | 2025-05-16 |
Family
ID=70284358
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021520923A Active JP7678748B2 (ja) | 2018-10-16 | 2019-10-16 | 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法 |
| JP2024031893A Pending JP2024063161A (ja) | 2018-10-16 | 2024-03-04 | 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法 |
| JP2025076487A Pending JP2025118759A (ja) | 2018-10-16 | 2025-05-02 | 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024031893A Pending JP2024063161A (ja) | 2018-10-16 | 2024-03-04 | 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法 |
| JP2025076487A Pending JP2025118759A (ja) | 2018-10-16 | 2025-05-02 | 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11938135B2 (https=) |
| EP (2) | EP4268822A3 (https=) |
| JP (3) | JP7678748B2 (https=) |
| KR (1) | KR20210094532A (https=) |
| CN (2) | CN121197400A (https=) |
| AU (2) | AU2019359872B2 (https=) |
| BR (1) | BR112021007237A2 (https=) |
| CA (1) | CA3116321A1 (https=) |
| DK (1) | DK3866799T3 (https=) |
| ES (1) | ES2973130T3 (https=) |
| FI (1) | FI3866799T3 (https=) |
| IL (1) | IL281623A (https=) |
| MX (1) | MX2021004387A (https=) |
| PL (1) | PL3866799T3 (https=) |
| PT (1) | PT3866799T (https=) |
| WO (1) | WO2020081741A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3866799T3 (pl) | 2018-10-16 | 2024-04-29 | The Johns Hopkins University | Kompozycje do leczenia zespołu ehlersa-danlosa o typie naczyniowym |
| EP4126957A4 (en) * | 2020-03-31 | 2024-07-24 | The Regents of the University of California | COMPOSITIONS AND METHODS FOR TREATING DYSREGULATED WOUND HEALING |
| EP4208203A4 (en) * | 2020-09-04 | 2024-09-04 | The Johns Hopkins University | TREATMENT OF VASCULAR EHLERS-DANLOS SYNDROME AND ASSOCIATED SYNDROMES |
| US20250144095A1 (en) * | 2022-02-03 | 2025-05-08 | The Johns Hopkins University | Compositions and methods for treatment of connective tissue disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| DE102004019413A1 (de) | 2004-04-19 | 2005-11-24 | Phenos Gmbh | Hemmung der Proteinkinase C epsilon zur Behandlung von Krankheiten |
| US20150119435A1 (en) * | 2012-05-11 | 2015-04-30 | Yale University | Compounds useful for promoting protein degradation and methods using same |
| US10730870B2 (en) * | 2015-03-18 | 2020-08-04 | Arvinas Operations, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| AU2016349279A1 (en) * | 2015-11-03 | 2018-05-10 | Board Of Regents, The University Of Texas System | Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancer |
| US11692028B2 (en) * | 2017-03-02 | 2023-07-04 | The Johns Hopkins University | Map kinase pathway targets for the treatment of Marfan syndrome |
| PL3866799T3 (pl) | 2018-10-16 | 2024-04-29 | The Johns Hopkins University | Kompozycje do leczenia zespołu ehlersa-danlosa o typie naczyniowym |
-
2019
- 2019-10-16 PL PL19872573.1T patent/PL3866799T3/pl unknown
- 2019-10-16 FI FIEP19872573.1T patent/FI3866799T3/fi active
- 2019-10-16 JP JP2021520923A patent/JP7678748B2/ja active Active
- 2019-10-16 DK DK19872573.1T patent/DK3866799T3/da active
- 2019-10-16 CA CA3116321A patent/CA3116321A1/en active Pending
- 2019-10-16 WO PCT/US2019/056616 patent/WO2020081741A2/en not_active Ceased
- 2019-10-16 EP EP23191111.6A patent/EP4268822A3/en active Pending
- 2019-10-16 KR KR1020217014599A patent/KR20210094532A/ko active Pending
- 2019-10-16 AU AU2019359872A patent/AU2019359872B2/en active Active
- 2019-10-16 CN CN202511337632.1A patent/CN121197400A/zh active Pending
- 2019-10-16 CN CN201980067015.0A patent/CN113194946B/zh active Active
- 2019-10-16 MX MX2021004387A patent/MX2021004387A/es unknown
- 2019-10-16 US US17/286,414 patent/US11938135B2/en active Active
- 2019-10-16 PT PT198725731T patent/PT3866799T/pt unknown
- 2019-10-16 ES ES19872573T patent/ES2973130T3/es active Active
- 2019-10-16 EP EP19872573.1A patent/EP3866799B1/en active Active
- 2019-10-16 BR BR112021007237-3A patent/BR112021007237A2/pt unknown
-
2021
- 2021-03-18 IL IL281623A patent/IL281623A/en unknown
-
2024
- 2024-02-07 US US18/435,769 patent/US20240408091A1/en active Pending
- 2024-03-04 JP JP2024031893A patent/JP2024063161A/ja active Pending
-
2025
- 2025-01-16 AU AU2025200315A patent/AU2025200315A1/en active Pending
- 2025-05-02 JP JP2025076487A patent/JP2025118759A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | CD36 plays a negative role in the regulation of lipophagy in hepatocytes through an AMPK-dependent pathway | |
| JP7344337B2 (ja) | ミオスタチン阻害剤の使用および併用療法 | |
| Li et al. | Alamandine attenuates sepsis-associated cardiac dysfunction via inhibiting MAPKs signaling pathways | |
| US11852634B2 (en) | Use of AKT phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same | |
| Zangerolamo et al. | The bile acid TUDCA improves glucose metabolism in streptozotocin-induced Alzheimer's disease mice model | |
| Chang et al. | Reversing LRP 5‐Dependent Osteoporosis and SOST Deficiency–Induced Sclerosing Bone Disorders by Altering WNT Signaling Activity | |
| Chen et al. | Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension | |
| Archer et al. | Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies | |
| Weger et al. | Hyperhomocyst (e) inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion | |
| Jünemann et al. | Agonistic autoantibodies to the β2-adrenergic receptor involved in the pathogenesis of open-angle glaucoma | |
| JP2022504990A5 (https=) | ||
| CN104244956A (zh) | 使用环糊精的方法 | |
| Kim et al. | Lower uncarboxylated osteocalcin and higher sclerostin levels are significantly associated with coronary artery disease | |
| EP2723391A2 (en) | Fibroblast growth factor receptor inhibition for the treatment of disease | |
| Zemankova et al. | Atorvastatin-induced endothelial nitric oxide synthase expression in endothelial cells is mediated by endoglin | |
| Barreto et al. | Prognostic implication of plasma osteopontin levels in patients with chronic kidney disease | |
| EP3089748A1 (en) | Treating ocular neovascularization | |
| Kumagai et al. | Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients | |
| Gamil et al. | Increased serum levels of asymmetric dimethylarginine and symmetric dimethylarginine and decreased levels of arginine in Sudanese patients with essential hypertension | |
| WO2021216548A1 (en) | Methods and compositions for treatment of age-related macular degeneration | |
| JPWO2020081741A5 (https=) | ||
| WO2024030909A1 (en) | Biomarkers of amino acid composition treatment response in long covid | |
| US20130302337A1 (en) | Methods and compositions for treating alzheimer's disease | |
| Yamagata et al. | Bactericidal/permeability‐increasing protein's signaling pathways and its retinal trophic and anti‐angiogenic effects | |
| JP6709493B2 (ja) | 進行性骨化性線維異形成症治療剤 |